Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)
China flag China · Delayed Price · Currency is CNY
19.68
-0.44 (-2.19%)
Sep 11, 2026, 3:04 PM CST

SHE:300204 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Cash & Equivalents
126.16123.6453.9185.18264.9985.01
Trading Asset Securities
-----381.46
Cash & Short-Term Investments
126.16123.6453.9185.18264.99466.47
Cash Growth
-27.14%129.34%-36.71%-67.86%-43.19%-35.44%
Accounts Receivable
37.6441.5239.0761.22188.18157.9
Other Receivables
0.921.220.641.141.381.18
Receivables
38.5642.7539.7262.35189.56159.07
Inventory
16.8819.322.1820.9318.8325.01
Prepaid Expenses
0.0300.010.01--
Other Current Assets
66.7466.9761.870.4155.6937.9
Total Current Assets
248.37252.65177.62238.89529.06688.44
Property, Plant & Equipment
201211.79235261.36290.58312.43
Long-Term Investments
497.18475.02514.07549.54522.25545.43
Goodwill
19.7519.7519.7519.7519.7522.17
Other Intangible Assets
147.0736.3634.6735.1380.4882.22
Long-Term Deferred Tax Assets
50.4250.4250.08164198.13155.84
Long-Term Deferred Charges
107.35186.77117.8462.5726.975.29
Other Long-Term Assets
31.8633.450.580.982.0915.15
Total Assets
1,3031,2661,1501,3321,6691,827

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Accounts Payable
15.5721.9233.4972.9135.8731.71
Accrued Expenses
38.7352.6967.7183.85158.73150.01
Short-Term Debt
81.992.2742.4240.9523.09-
Current Portion of Leases
0.270.430.06-2.692.25
Current Income Taxes Payable
-0--0.02-
Current Unearned Revenue
0.961.263.892.863.271.34
Other Current Liabilities
6.246.996.887.68.111.33
Total Current Liabilities
143.68175.55154.45208.17231.77196.64
Long-Term Leases
0.480.670.06-3.185.37
Long-Term Unearned Revenue
25.2926.7629.9129.2433.4721.32
Long-Term Deferred Tax Liabilities
49.2449.2448.4374.1447.0352.91
Other Long-Term Liabilities
213.22207.27----
Total Liabilities
511.97459.48232.85311.55315.45276.25

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Common Stock
477.77477.77477.77477.77475.36476.03
Additional Paid-In Capital
558.6558.6570.95534.46519.36536.44
Retained Earnings
-368.47-327.12-249.37-83.63314.62510.98
Treasury Stock
------43.68
Comprehensive Income & Other
139.28111.53129.8892.0644.5370.97
Total Common Equity
807.18820.78929.231,0211,3541,551
Minority Interest
-16.15-14.06-12.47---
Shareholders' Equity
791.03806.72916.761,0211,3541,551
Total Liabilities & Equity
1,3031,2661,1501,3321,6691,827

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Total Debt
162.7193.3642.5440.9528.967.63
Net Cash (Debt)
-36.5530.2811.3744.23236.03458.84
Net Cash Growth
-166.24%-74.28%-81.26%-48.56%-31.98%
Net Cash Per Share
-0.080.060.020.090.490.97
Filing Date Shares Outstanding
477.77477.77477.77477.77475.36472.66
Total Common Shares Outstanding
477.77477.77477.77477.77475.36472.66
Working Capital
104.6977.123.1830.72297.28491.8
Book Value Per Share
1.691.721.942.142.853.28
Tangible Book Value
640.36764.67874.81965.781,2541,446
Tangible Book Value Per Share
1.341.601.832.022.643.06
Buildings
215.45215.73215.93214.75184.57183.64
Machinery
303.38302.85317.62318.38254.98246.28
Construction In Progress
----87.8285.48